What topics does this cannabis study cover?

This study covers research on: Inflammation.

Where was this research published?

Published in The American journal of medicine on June 27, 2026.

Cannabis linked to heart attacks in younger, healthier adults

Q: What did this Review find?

Cannabis use has emerged as a **potentially significant risk factor for heart attacks**, particularly in younger adults without traditional cardiovascular disease markers. This research paper examines the mechanistic pathways through which marijuana precipitates acute myocardial infarction, revealin

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine • June 27, 2026 • Review • Moderately Relevant

🤖

AI Summary

Cannabis use has emerged as a potentially significant risk factor for heart attacks, particularly in younger adults without traditional cardiovascular disease markers. This research paper examines the mechanistic pathways through which marijuana precipitates acute myocardial infarction, revealing a complex interplay of physiological disruptions. THC activates the sympathetic nervous system, increasing heart workload and oxygen demand, while simultaneously impairing oxygen delivery through elevated carboxyhemoglobin levels. Additionally, cannabis triggers coronary vasospasm (sudden narrowing of heart vessels), causes endothelial dysfunction, and promotes a prothrombotic state with enhanced platelet activation—all factors that work together to increase heart attack risk.

The paper highlights critical individual variations in cannabis-related cardiovascular risk based on genetic differences in cannabinoid receptor expression and how the body metabolizes THC through the CYP2C9 enzyme system. For patients with existing coronary artery disease, frequent cannabis use appears to elevate cardiovascular risk, though research remains limited. A particularly important clinical concern involves CBD's inhibition of CYP2C19 enzymes, which may impair how the body activates clopidogrel, a critical blood-thinning medication used after heart procedures. This drug interaction could leave post-intervention patients vulnerable to dangerous blood clots.

These findings underscore the urgent need for cannabis use screening in clinical practice, especially for younger patients experiencing chest pain or cardiac events. As cannabis legalization spreads and usage rates continue climbing, healthcare providers must recognize marijuana as a modifiable cardiovascular risk factor. The research emphasizes that more prospective studies are essential to develop evidence-based management strategies and better understand individual susceptibility factors.

📄 Original Abstract

Marijuana, or cannabis, is the most commonly used illicit substance in the United States, with prevalence nearly doubling over the past decade. Accumulating evidence implicates cannabis use as a potentially modifiable risk factor for acute myocardial infarction, particularly among younger adults without traditional cardiovascular risk factors. Marijuana precipitates acute myocardial infarction through multiple converging mechanisms: increased myocardial oxygen demand via sympathetic activation, impaired oxygen delivery through carboxyhemoglobin elevation, coronary vasospasm, endothelial dysfunction, and a prothrombotic state characterized by enhanced platelet activation. Genetic variability in cannabinoid receptor expression and CYP2C9-mediated tetrahydrocannabinol metabolism further modulates individual susceptibility. Among patients with established coronary artery disease, population-based data suggest elevated cardiovascular risk with frequent use, though prospective cohort data remain conflicting. In post-percutaneous coronary intervention patients on dual antiplatelet therapy, cannabidiol inhibition of CYP2C19 may impair clopidogrel bioactivation, warranting consideration of alternative P2Y12 inhibitors. These findings highlight the importance of cannabis use screening in clinical practice and the need for prospective studies to guide evidence-based management.

Paper Type

📚 Review

Publication

Journal: The American journal of medicine
Published: June 27, 2026
PMID: 42364797
DOI: 10.1016/j.amjmed.2026.06.014

Authors (9)

Sarib Sultan Sam Houston State University College of Osteopathic Medicine (SHSU-COM), Texas, USA; Lincoln Memorial University-DeBusk College of Osteopathic Medicine (LMU-DCOM), Tennessee, USA; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Office of the Vice Provost (Research), The Aga Khan University, Karachi 74800, Pakistan; John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA; Penn Highlands Healthcare, Pennsylvania, USA.
Adeel Ahmed Sam Houston State University College of Osteopathic Medicine (SHSU-COM), Texas, USA; Lincoln Memorial University-DeBusk College of Osteopathic Medicine (LMU-DCOM), Tennessee, USA; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Office of the Vice Provost (Research), The Aga Khan University, Karachi 74800, Pakistan; John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA; Penn Highlands Healthcare, Pennsylvania, USA.
Yasmin Obeidi Sam Houston State University College of Osteopathic Medicine (SHSU-COM), Texas, USA; Lincoln Memorial University-DeBusk College of Osteopathic Medicine (LMU-DCOM), Tennessee, USA; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Office of the Vice Provost (Research), The Aga Khan University, Karachi 74800, Pakistan; John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA; Penn Highlands Healthcare, Pennsylvania, USA.
Mohammad Mahdi Sam Houston State University College of Osteopathic Medicine (SHSU-COM), Texas, USA; Lincoln Memorial University-DeBusk College of Osteopathic Medicine (LMU-DCOM), Tennessee, USA; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Office of the Vice Provost (Research), The Aga Khan University, Karachi 74800, Pakistan; John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA; Penn Highlands Healthcare, Pennsylvania, USA.
Sarim Sultan Sam Houston State University College of Osteopathic Medicine (SHSU-COM), Texas, USA; Lincoln Memorial University-DeBusk College of Osteopathic Medicine (LMU-DCOM), Tennessee, USA; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Office of the Vice Provost (Research), The Aga Khan University, Karachi 74800, Pakistan; John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA; Penn Highlands Healthcare, Pennsylvania, USA.
+4 more authors